23:50:11 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2022-08-23 11:51:00

PolarCool AB (publ) has entered into an agreement with the United Rugby Championship team, Scarlets, for the use of the PolarCap® System. The agreement marks an important breakthrough for PolarCool in UK Rugby.

PolarCool develops and markets the product PolarCap® which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, and handball.

The agreement with the Scarlets means that PolarCap® will be used by the team during the start of the United Rugby Championship in an initial trial period, with the aim to transition into a two-year commercial agreement following the trial. The deal marks a strategic introduction for PolarCap® within UK Rugby and the United Rugby Championship.

Rugby is one of PolarCool's most important markets, as the sport has more than 180,000 clubs and 6.6 million players globally. The concussion rate in rugby is high putting rugby players at a larger risk of injury compared to athletes in other sports. PolarCool are currently in discussions with several rugby clubs both in France and England, where the interest in reducing the effects of the injury is high.

PolarCool's CEO Erik Andersson comments:

-In our ongoing establishment on the British market, it is now gratifying that we have received our first agreement within UK Rugby. We notice that the wish for solutions regarding the problems with head injuries in the rugby world is large. With this first and more to come agreements we envisage an increased awareness of the possibility of treatment with PolarCap® System and thereby an accelerating establishment in this market aw well as also in other sports on the UK.

The Scarlets are one of the four professional Welsh rugby union teams and are based in Llanelli, Wales, UK. They have a rich history of success and are known for producing some of the best rugby players in the world. They play in the United Rugby Championship and the European Rugby Champions Cup.